Castle Bio (CSTL) Q3 2026 Earnings Call Transcript

Castle Biosciences reported Q3 2026 revenue of $102.9 million, up 24% year over year, and raised its full-year revenue guidance by $20 million at the midpoint to $385 million–$395 million, driven mainly by TissueCypher volume growth of 47%. Adjusted EBITDA increased to $12.7 million from $9.2 million, operating cash flow was $19.7 million, and cash and marketable securities totaled approximately $278 million, although the company reported a $4.1 million net loss. Management expects positive adjusted EBITDA for 2026 and 2027; it did not assume recovery of Medicare coverage for DecisionDx-SCC in its 2027 revenue plans and noted that Q4 can be seasonally lighter.

Analysis

CSTL’s key asset is increasingly the adoption curve in TissueCypher, not simply this quarter’s beat. Growth led more by deeper use among existing clinicians than new prescribers suggests monetization headroom, but also makes repeat utilization and payer acceptance more important than headline addressable-market estimates. The 15% penetration figure is not evidence that the remaining procedures are readily convertible; clinical workflow, reimbursement and evidence standards can slow that curve.

Near term, Q4 seasonality creates a risk of an optically flat sequential result despite management’s full-year outlook. That could invite a sell-the-news response; distinguish operating-day noise from a change in clinician utilization. Over 1–3 months, the more consequential catalysts are the CMS pricing decision for AdvanceAD-Tx and progress toward a draft LCD for DecisionDx-SCC. Neither should be capitalized as a near-term earnings driver until pricing or coverage is final. SCC coverage recovery is explicitly not embedded in the 2027 plan, limiting downside from that issue but also deferring upside.

The margin story is less clean than adjusted EBITDA suggests: stable adjusted gross margin alongside rising lab costs and headcount means volume growth requires ongoing capacity investment, while GAAP losses and stock compensation remain relevant to per-share value. A decision-modeling study supports clinical utility but does not establish prospective outcomes or payer economics. Over 6–18 months, verify whether rep productivity and reimbursement convert growth into operating leverage. Personalized-vaccine-related demand is a long-dated option, not an underwriting case today.

Key Decisions for Investors

• CSTL: favor a measured long, adding on post-earnings weakness rather than chasing the print. The thesis is continued TissueCypher adoption with stable realized pricing; size it as a growth position given reimbursement and utilization uncertainty.
• For the next 1–3 months, monitor the CMS AdvanceAD-Tx pricing outcome and any DecisionDx-SCC draft LCD. Treat either as a catalyst only after the actual pricing/coverage terms are known; do not book SCC recovery into near-term estimates.
• Track TissueCypher reports, ASP and adjusted gross margin together. Reassess the long if volume momentum materially undercuts management’s 2026 growth outlook, realized pricing weakens, or margin deterioration shows capacity costs are outpacing revenue.
• Expect Q4 practice-calendar noise to distort sequential comparisons. A sequential slowdown alone is not thesis-breaking; weaker clinician utilization or a downward revenue outlook would be.